Unit 1 Part 2 Blood Collection

Download Report

Transcript Unit 1 Part 2 Blood Collection

Unit 1 Part 2 Blood Collection
Terry Kotrla, MS, MT(ASCP)BB
MLAB 2431 Immunohematology
Blood Collection
Collection of Blood
 Collection performed by well trained personnel.
 Materials used are FDA approved sterile and single use.
 Donor identification critical
 Identify donor record with donor
 Attach numbered labels
 Label processing tubes
 Final recheck before leaving donor
Preparing Site
 Inspect BOTH arms for signs of IV drug abuse.
 Select large firm vein in area free of scarring or skin lesions.
 Vein selection priority same as for routine phlebotomy.
 Most important step is preparing the site to a state of almost
surgical cleanliness.
 Bacteria on skin, if present, may grow well in stored donor blood
and cause a fatal sepsis in recipient
Blood Collection
 Gloves are optional, OSHA provides specific exemption for
drawing volunteer donors.
 Gloves should be worn:
 By personnel in training
 Collecting autologous units
 If employee has cuts, scratches or breaks in skin.
 Use 16-17 gauge needle to collect blood from a single
venipuncture within 10 minutes.
 First 30 to 45 mLs of blood diverted to pouch to collect skin
plug.
 Mix blood bag frequently or use shaker.
 Collect 450 or 500 mLs +/- 10% of blood
Blood Collection System
Donor Reactions
 Syncope (fainting)
 Remove needle immediately
 Hyperventilation
 Have donor rebreathe into paper bag.
 Nausea/vomiting
 Twitching/muscle spasms
 Hematoma
 Upper extremity deep vein thrombosis
 Convulsions – rare, get immediate assistance
 Cardiac difficulties – get emergency care
 Record ANY donor reactions
Post-Phlebotomy Care
 Donor applies pressure for 5 minutes with arm elevated.
 Check and bandage site
 Have donor sit up for few minutes
 Have donor report to refreshment area for additional 15
minutes of monitoring
Post-Phlebotomy Instructions
 Eat/drink before leaving
 Wait until staff releases you
 Drink more fluids next 4 hours
 No alcohol until after eating
 Refrain from smoking for 30 minutes.
 If bleeding continues apply pressure and raise arm
 Faint or dizzy sit with head between knees
 Abnormal symptoms persist contact blood center.
 Cautions about returning to work.
 Let them know when to remove bandage
Post-Phlebotomy Instructions
 In canteen provide donor refreshments and watch for signs of
a reaction.
 Provide phone number for donor to call if:
 bleeding recurs
 feels donated unit should not be used
 has any type of reaction.
 experiences signs or symptoms of infection.
 THANK DONOR
Processing Donor Blood
 All reagents used for testing must meet or exceed
appropriate FDA regulations.
 CANNOT rely on previous testing
 Results recorded immediately.
 Record system to track unit to final disposition.
 Records must be retrievable.
 Records must be kept for 5 years OR 6 months after product
expires.
General Considerations
 Numbers on blood bag, processing tubes and donor
records should be rechecked prior to processing.
 ABO group and D type, including weak D
 Donor with history of transfusion or pregnancy should
be tested for unexpected antibodies.
Serological Testing
 ABO/D typing
 Antibody Screen – if positive, ID antibody, cannot make
plasma products
 Antibodies to other blood group antigens which are present
in the donor may react with recipient red cells resulting in a
reaction.
Infectious Disease Testing Methods
 ELISA to detect antigens or antibodies
 Chemiluminescent to detect antigens or antibodies
 Detection of syphilis antibodies by RPR
 Nucleic Acid Test (NAT) detects viral nucleic acids, much
more sensitive, reduces window period
 HIV from 22 to 12 days
 HCV from 70 to 10-14 days
 Antigen, antibody and NAT testing will allow positive results
through out disease process.
Disease Testing
 Disease testing include:
 Dectection of bacteria
 HBsAG
 Anti-HBc
 Anti-HCV
 Anti-HIV 1&2
 Anti-HTLV I/II
 RPR
 Chagas disease antibodies
 NAT for
 HIV-1,
 HCV
 WNV
Results of Testing
 Tests for disease markers must be negative or within normal
limits.
 Donor blood which falls outside these parameters must be
quarrantined.
 Repeat testing, if still abnormal must dispose.
Optional Tests
 CMV testing
 CMV devastating to premature infants and
immunocompromised
 Removing leukocytes greatly reduces risk.
 Some physicians still request CMV negative for select patients
 Special antigen typing
 Patients may develop antibodies against other RBC antigens.
 Test donors to find antigen negative
 Sickle cell testing
 Exchange transfusion
 Sickle trait may sickle in neonates
Labeling Donor Units
 Component name
 Unique donor number
 ABO group, D type (not required for plasma)
 Interpretation of tests
 Type and volume of anticoagulant.
 Storage temperature
 Expiration date
 Name/address of collecting facility
 Reference to Circular of Information 



http://www.aabb.org/Content/About_Blood/Circulars_of_Information/
Donor classification
Results of testing
Essential instructions
Pooled component information
Transfusion Service Testing
 The only repeat testing required is:
 ABO on red cell products
 D typing (IS) on D negative red cell products
 Plasma products (FFP, CRYO, PLTS) do not require any testing.
 Donor samples must be stored at 1-6C for at least 7 days after
transfusion
 ADSOL unit transfused today must save sprig for 7 days post-transfusion.
 Many facilities will pull a sprig from each donor during processing and save
all sprigs for 49 days, regardless of expiration of unit
Red Cell Unit With Sprigs
Summary
 Blood collection starts with screening of the donor to:
 Ensure they are healthy enough to donate
 Ensure they do not have transmissible diseases
 Many organizations involved in setting standards and monitoring all aspects of
blood collection and administration.
 Collection of blood must be done in such a manner as to ensure sterility of the
component.
 Testing of donor blood includes serological testing for ABO/D typing, antibody
screening and testing for infectious disease markers.
 The blood supply is NOT safe, only careful screening and testing can prevent, as
much as possible, disease transmission.
References
 AABB Technical Manual 16th edition
 http://www.fda.gov/cber/dhq/dhq.htm